Holen Sie sich die Stockscreener-App
9.22
2.64%
-0.25
Handel nachbörslich:
9.22
Schlusskurs vom Vortag:
$9.47
Offen:
$9.49
24-Stunden-Volumen:
261.65K
Relative Volume:
0.89
Marktkapitalisierung:
$548.26M
Einnahmen:
$2.91M
Nettoeinkommen (Verlust:
$-220.40M
KGV:
-1.7495
EPS:
-5.27
Netto-Cashflow:
$-176.15M
1W Leistung:
-28.42%
1M Leistung:
-44.86%
6M Leistung:
+0.00%
1J Leistung:
+53.41%
1-Tages-Spanne:
$8.58
$9.59
1-Wochen-Bereich:
$8.58
$13.55
52-Wochen-Spanne:
$4.72
$22.50
Igm Biosciences Inc Stock (IGMS) Company Profile
Firmenname
Igm Biosciences Inc
Sektor
Branche
Telefon
650-965-7873
Adresse
325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW
Vergleichen Sie IGMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| IGMS | 9.22 | 548.26M | 2.91M | -220.40M | -176.15M | -5.27 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-09 | Fortgesetzt | Jefferies | Buy |
| 2022-10-17 | Eingeleitet | JP Morgan | Neutral |
| 2022-08-29 | Eingeleitet | BofA Securities | Buy |
| 2021-12-13 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-05 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-08-26 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-01-29 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-01-19 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-22 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-07-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-07-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-28 | Eingeleitet | SunTrust | Buy |
| 2020-04-22 | Eingeleitet | Wedbush | Outperform |
| 2019-10-14 | Eingeleitet | Guggenheim | Buy |
| 2019-10-14 | Eingeleitet | Jefferies | Buy |
| 2019-10-14 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-10-14 | Eingeleitet | Stifel | Buy |
Alle ansehen
Igm Biosciences Inc Aktie (IGMS) Neueste Nachrichten
Will Imvotamab Data Propel IGM Biosciences To New Heights In 2025? - RTTNews
IGM Biosciences' SWOT analysis: stock pivot to autoimmune focus sparks analyst optimism - Investing.com
How To Trade (IGMS) - Stock Traders Daily
FMR LLC Increases Stake in IGM Biosciences Inc - GuruFocus.com
IGM Biosciences Insiders Who Sold Avert US$165m Market Cap Dip - Simply Wall St
Biotech firm backs off its focus on oncology research - The Business Journals
IGM Biosciences (NASDAQ:IGMS) Given New $27.00 Price Target at Stifel Nicolaus - MarketBeat
Igm Biosciences: Navigating Financial Challenges Amidst Early-Stage Antibody Development - MSN
IGM Biosciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
IGM Biosciences (NASDAQ:IGMS) Shares Down 7.8%Here's Why - MarketBeat
IGM Biosciences Inc (IGMS) Quarterly 10-Q Report - Quartz
IGM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
IGM Biosciences earnings missed by $0.21, revenue topped estimates - Investing.com UK
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
IGM Biosciences Reports $61.4M Loss, Extends Cash Runway to 2027 Despite Clinical Progress | IGMS Stock News - StockTitan
IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
IGM Biosciences to Present at Three Upcoming Investor Conferences - GlobeNewswire
(IGMS) Investment Report - Stock Traders Daily
IGM Biosciences (NASDAQ:IGMS) Shares Down 3.7%Should You Sell? - MarketBeat
Brokerages Set IGM Biosciences, Inc. (NASDAQ:IGMS) PT at $15.00 - Defense World
IGM Biosciences (NASDAQ:IGMS) Trading 7.7% HigherHere's Why - MarketBeat
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
IGM Biosciences' SWOT analysis: autoimmune pivot drives stock outlook - Investing.com India
IGM Biosciences' SWOT analysis: autoimmune pivot drives stock outlook By Investing.com - Investing.com South Africa
Exchange Traded Concepts LLC Trims Holdings in IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences’ stock tumbles as analysts weigh in on pivot plan with dismay - MSN
IGM Biosciences (NASDAQ:IGMS) Shares Down 6.1%Here's What Happened - MarketBeat
IGM Biosciences (NASDAQ:IGMS) PT Raised to $20.00 at Royal Bank of Canada - Defense World
AQR Capital Management LLC Acquires Shares of 12,230 IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) PT Raised to $20.00 - MarketBeat
IGM Biosciences (NASDAQ:IGMS) Shares Up 8%Here's What Happened - MarketBeat
IGM Biosciences, Inc. (NASDAQ:IGMS) Short Interest Down 23.9% in September - MarketBeat
IGM Biosciences (NASDAQ:IGMS) Shares Down 5.5%Time to Sell? - MarketBeat
Dimensional Fund Advisors LP Lowers Position in IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) Trading Up 8.1%Here's What Happened - MarketBeat
Marshall Wace LLP Has $737,000 Stock Holdings in IGM Biosciences, Inc. (NASDAQ:IGMS) - MarketBeat
IGM Biosciences (NASDAQ:IGMS) Trading 10.1% Higher – Here’s What Happened - Defense World
IGM Biosciences (NASDAQ:IGMS) Trading Up 10.1%Time to Buy? - MarketBeat
IGM Biosciences Shifts Focus to Autoimmunity, Appoints New CEO - TipRanks
IGM Biosciences downgraded to Hold, stock falls - MSN
Wedbush Comments on IGM Biosciences, Inc.'s Q3 2024 Earnings (NASDAQ:IGMS) - MarketBeat
Wedbush Comments on IGM Biosciences, Inc.’s Q3 2024 Earnings (NASDAQ:IGMS) - Defense World
The Attractiveness of Investing In IGM Biosciences Inc (IGMS) is Growing - Knox Daily
IGM Biosciences (NASDAQ:IGMS) Trading Down 7.4% Following Analyst Downgrade - MarketBeat
Balance Sheet Insights: IGM Biosciences Inc (IGMS)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Guggenheim Trims IGM Biosciences (NASDAQ:IGMS) Target Price to $20.00 - Defense World
IGM Biosciences, Inc. (NASDAQ:IGMS) Expected to Earn Q2 2025 Earnings of ($0.38) Per Share - MarketBeat
Finanzdaten der Igm Biosciences Inc-Aktie (IGMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):